Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $815 from $810 on August 4, keeping a Buy rating on the shares.

The analyst told investors in a post-earnings note that the company’s fiscal Q2 performance exceeded investor expectations due to solid Dupixent sales and “a good performance from a struggling Eylea franchise.”

Suneja added that management made “some interesting comments on the call regarding BD strategy,” suggesting that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is now open to considering “differentiated later-stage opportunities in areas with high unmet medical need” compared to its previous focus on early-stage assets.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.